close

Fundraisings and IPOs

Date: 2018-10-10

Type of information: Private placement

Company: Histogenics (USA - MA)

Investors:

Amount: $15.4 million

Funding type: private placement

Planned used:

  • Histogenics intends to use the net proceeds from the offering to complete the submission of the NeoCart® biologics license application and prepare for commercialization of NeoCart following approval by the FDA, if at all, and for general corporate purposes.

Others:

  • • On October 10, 2018, Histogenics announced the closing of its previously announced underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The net proceeds to Histogenics from this offering are approximately $15.4 million, after deducting underwriting discounts and commissions, and estimated offering expenses payable by Histogenics.
  • • On October 5, 2018, Histogenics announced the pricing of an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The gross proceeds to Histogenics from this offering are expected to be $17.0 million, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics. The warrants are exercisable immediately upon issuance at a price of $0.70 per share of common stock and have a term of five years commencing on the date of issuance. The offering is expected to close on or about October 10, 2018, subject to customary closing conditions. Canaccord Genuity LLC and BTIG, LLC are acting as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as the co-manager for the offering. CIM Securities, LLC acted as a financial advisor to Histogenics in connection with the offering.
  • • On October 4, 2018, Histogenics announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities in the offering are to be sold by Histogenics.

Therapeutic area: Regenerative Medicine - Bone diseases

Is general: Yes